Human Investing LLC Sells 417 Shares of Novo Nordisk A/S (NYSE:NVO)

Human Investing LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,873 shares of the company’s stock after selling 417 shares during the quarter. Novo Nordisk A/S makes up about 0.5% of Human Investing LLC’s investment portfolio, making the stock its 26th biggest position. Human Investing LLC’s holdings in Novo Nordisk A/S were worth $2,723,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of NVO. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Novo Nordisk A/S by 14.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock valued at $34,463,000 after acquiring an additional 37,346 shares during the period. Independence Bank of Kentucky increased its holdings in Novo Nordisk A/S by 192.7% in the third quarter. Independence Bank of Kentucky now owns 11,490 shares of the company’s stock valued at $1,368,000 after purchasing an additional 7,565 shares during the last quarter. Traynor Capital Management Inc. lifted its stake in Novo Nordisk A/S by 3.4% in the third quarter. Traynor Capital Management Inc. now owns 305,404 shares of the company’s stock valued at $36,364,000 after buying an additional 10,019 shares during the period. Cetera Investment Advisers grew its holdings in Novo Nordisk A/S by 453.3% during the first quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock valued at $34,095,000 after purchasing an additional 217,545 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Novo Nordisk A/S during the second quarter worth $1,624,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on NVO shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. Finally, BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average target price of $144.50.

Novo Nordisk A/S Stock Up 0.3 %

NYSE NVO traded up $0.31 during trading hours on Friday, hitting $112.26. 1,333,050 shares of the company traded hands, compared to its average volume of 4,348,367. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The business’s 50-day moving average is $124.75 and its 200-day moving average is $130.93. The stock has a market capitalization of $503.77 billion, a price-to-earnings ratio of 38.41, a P/E/G ratio of 1.48 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The firm had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.01 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were issued a dividend of $0.5126 per share. This represents a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio is 24.66%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.